Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Published:April 16, 2022DOI:


      • Combining therapies with complementary mechanisms may be beneficial in patients with NASH.
      • In a phase II trial in 108 patients with NASH, semaglutide alone or in combination with cilofexor and/or firsocostat was well tolerated.
      • Combinations resulted in greater improvements in liver steatosis, liver biochemistry, and non-invasive tests of fibrosis.

      Background & Aims

      Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This trial evaluated the safety and efficacy of semaglutide, a glucagon-like peptide-1 receptor agonist, alone and in combination with the farnesoid X receptor agonist cilofexor and/or the acetyl-coenzyme A carboxylase inhibitor firsocostat in patients with NASH.


      This was a phase II, open-label, proof-of-concept trial in which patients with NASH (F2–F3 on biopsy, or MRI-proton density fat fraction [MRI-PDFF] ≥10% and liver stiffness by transient elastography ≥7 kPa) were randomised to 24 weeks’ treatment with semaglutide 2.4 mg once weekly as monotherapy or combined with once-daily cilofexor (30 or 100 mg) and/or once-daily firsocostat 20 mg. The primary endpoint was safety. All efficacy endpoints were exploratory.


      A total of 108 patients were randomised to semaglutide (n = 21), semaglutide plus cilofexor 30 mg (n = 22), semaglutide plus cilofexor 100 mg (n = 22), semaglutide plus firsocostat (n = 22) or semaglutide, cilofexor 30 mg and firsocostat (n = 21). Treatments were well tolerated – the incidence of adverse events was similar across groups (73–90%) and most events were gastrointestinal in nature. Despite similar weight loss (7–10%), compared with semaglutide monotherapy, combinations resulted in greater improvements in liver steatosis measured by MRI-PDFF (least-squares mean of absolute changes: −9.8 to −11.0% vs. −8.0%), liver biochemistry, and non-invasive tests of fibrosis.


      In patients with mild-to-moderate fibrosis due to NASH, semaglutide with firsocostat and/or cilofexor was generally well tolerated. In exploratory efficacy analyses, treatment resulted in additional improvements in liver steatosis and biochemistry vs. semaglutide alone. Given this was a small-scale open-label trial, double-blind placebo-controlled trials with adequate patient numbers are warranted to assess the efficacy and safety of these combinations in NASH.

      Clinical Trial registration number


      Lay summary

      Non-alcoholic fatty liver disease and its more severe form, non-alcoholic steatohepatitis (NASH), are serious liver conditions that worsen over time if untreated. The reasons people develop NASH are complex and combining therapies that target different aspects of the disease may be more helpful than using single treatments. This trial showed that the use of 3 different types of drugs, namely semaglutide, cilofexor and firsocostat, in combination was safe and may offer additional benefits over treatment with semaglutide alone.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chalasani N.
        • Younossi Z.
        • Lavine J.E.
        • Charlton M.
        • Cusi K.
        • Rinella M.
        • et al.
        The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
        Hepatology. 2018; 67: 328-357
        • Loomba R.
        MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.
        Hepatology. 2021; 73: 881-888
        • Noureddin M.
        • Vipani A.
        • Bresee C.
        • Todo T.
        • Kim I.K.
        • Alkhouri N.
        • et al.
        NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances.
        Am J Gastroenterol. 2018; 113: 1649-1659
        • Ekstedt M.
        • Hagström H.
        • Nasr P.
        • Fredrikson M.
        • Stål P.
        • Kechagias S.
        • et al.
        Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
        Hepatology. 2015; 61: 1547-1554
        • Golabi P.
        • Fukui N.
        • Paik J.
        • Sayiner M.
        • Mishra A.
        • Younossi Z.M.
        Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease.
        Hepatol Commun. 2019; 3: 1050-1060
        • Vuppalanchi R.
        • Noureddin M.
        • Alkhouri N.
        • Sanyal A.J.
        Therapeutic pipeline in nonalcoholic steatohepatitis.
        Nat Rev Gastroenterol Hepatol. 2021; 18: 373-392
        • Marra F.
        • Svegliati-Baroni G.
        Lipotoxicity and the gut-liver axis in NASH pathogenesis.
        J Hepatol. 2018; 68: 280-295
        • Cariou B.
        • Byrne C.D.
        • Loomba R.
        • Sanyal A.J.
        Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review.
        Diabetes Obes Metab. 2021; 23: 1069-1083
        • Loomba R.
        • Kayali Z.
        • Noureddin M.
        • Ruane P.
        • Lawitz E.J.
        • Bennett M.
        • et al.
        GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2018; 155: 1463-1473
        • Patel K.
        • Harrison S.A.
        • Elkhashab M.
        • Trotter J.F.
        • Herring R.
        • Rojter S.E.
        • et al.
        Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial.
        Hepatology. 2020; 72: 58-71
        • Loomba R.
        • Noureddin M.
        • Kowdley K.V.
        • Kohli A.
        • Sheikh A.
        • Neff G.
        • et al.
        Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH.
        Hepatology. 2021; 73: 625-643
        • Taylor-Weiner A.
        • Pokkalla H.
        • Han L.
        • Jia C.
        • Huss R.
        • Chung C.
        • et al.
        A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH.
        Hepatology. 2021; 74: 133-147
        • Sorli C.
        • Harashima S.I.
        • Tsoukas G.M.
        • Unger J.
        • Karsbøl J.D.
        • Hansen T.
        • et al.
        Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
        Lancet Diabetes Endocrinol. 2017; 5: 251-260
        • Newsome P.
        • Francque S.
        • Harrison S.
        • Ratziu V.
        • Van Gaal L.
        • Calanna S.
        • et al.
        Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
        Aliment Pharmacol Ther. 2019; 50: 193-203
        • Wilding J.P.H.
        • Batterham R.L.
        • Calanna S.
        • Davies M.
        • Van Gaal L.F.
        • Lingvay I.
        • et al.
        Once-weekly semaglutide in adults with overweight or obesity.
        N Engl J Med. 2021; 384: 989-1002
        • Marso S.P.
        • Bain S.C.
        • Consoli A.
        • Eliaschewitz F.G.
        • Jódar E.
        • Leiter L.A.
        • et al.
        Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
        N Engl J Med. 2016; 375: 1834-1844
        • Newsome P.N.
        • Buchholtz K.
        • Cusi K.
        • Linder M.
        • Okanoue T.
        • Ratziu V.
        • et al.
        A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.
        N Engl J Med. 2021; 384: 1113-1124
        • Dufour J.F.
        • Caussy C.
        • Loomba R.
        Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges.
        Gut. 2020; 69: 1877-1884
        • Newsome P.N.
        • Sasso M.
        • Deeks J.J.
        • Paredes A.
        • Boursier J.
        • Chan W.K.
        • et al.
        FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
        Lancet Gastroenterol Hepatol. 2020; 5: 362-373
        • Htike Z.Z.
        • Zaccardi F.
        • Papamargaritis D.
        • Webb D.R.
        • Khunti K.
        • Davies M.J.
        Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis.
        Diabetes Obes Metab. 2017; 19: 524-536
        • Younossi Z.M.
        • Wong V.W.
        • Anstee Q.M.
        • Romero-Gomez M.
        • Trauner M.H.
        • Harrison S.A.
        • et al.
        Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes.
        Hepatol Commun. 2020; 4: 1637-1650
        • Younossi Z.M.
        • Ratziu V.
        • Loomba R.
        • Rinella M.
        • Anstee Q.M.
        • Goodman Z.
        • et al.
        Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
        Lancet. 2019; 394: 2184-2196
        • Flint A.
        • Andersen G.
        • Hockings P.
        • Johansson L.
        • Morsing A.
        • Palle M.S.
        • et al.
        Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
        Aliment Pharmacol Ther. 2021; 54: 1150-1161
        • Loomba R.
        • Neuschwander-Tetri B.A.
        • Sanyal A.
        • Chalasani N.
        • Diehl A.M.
        • Terrault N.
        • et al.
        Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH.
        Hepatology. 2020; 72: 1219-1229
        • Stine J.G.
        • Munaganuru N.
        • Barnard A.
        • Wang J.L.
        • Kaulback K.
        • Argo C.K.
        • et al.
        Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2021; 19: 2274-2283.e5
        • Angulo P.
        • Kleiner D.E.
        • Dam-Larsen S.
        • Adams L.A.
        • Bjornsson E.S.
        • Charatcharoenwitthaya P.
        • et al.
        Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2015; 149: 389-397.e10
        • Sanyal A.J.
        • Harrison S.A.
        • Ratziu V.
        • Abdelmalek M.F.
        • Diehl A.M.
        • Caldwell S.
        • et al.
        The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.
        Hepatology. 2019; 70: 1913-1927
        • Harrison S.A.
        • Wong V.W.
        • Okanoue T.
        • Bzowej N.
        • Vuppalanchi R.
        • Younes Z.
        • et al.
        Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials.
        J Hepatol. 2020; 73: 26-39
        • Boursier J.
        • Loomba R.
        • Anstee Q.
        • Harrison S.
        • Sanyal A.
        • Rinella M.
        • et al.
        Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study.
        J Hepatol. 2020; 73 (AS075): S54
        • Vilar-Gomez E.
        • Martinez-Perez Y.
        • Calzadilla-Bertot L.
        • Torres-Gonzalez A.
        • Gra-Oramas B.
        • Gonzalez-Fabian L.
        • et al.
        Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.
        Gastroenterology. 2015; 149: 367-378.e5